Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-05-30T08:09:21Z | - |
dc.date.available | 2018-05-30T08:09:21Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.citation | COLLOIDS AND SURFACES B-BIOINTERFACES, v. 152, Page. 183-191 | en_US |
dc.identifier.issn | 0927-7765 | - |
dc.identifier.issn | 1873-4367 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0927776517300267 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/71728 | - |
dc.description.abstract | Anticancer drug targeting to liver asialoglycoprotein receptors (ASGPR) is viewed as a good approach for hepatocellular carcinoma (HCC) treatment. Lactose residue is a promising ASGPR ligand due to its high receptor affinity. Herein, we introduce doxorubicin and paclitaxel co-bound lactosylated albumin (Lac-BSA) nanoparticles (Dox/Pac Lac-BSA NPs) with good liver targetability. Lac-BSA was synthesized by conjugating lactobionic acid to naive BSA then characterized by mass spectrometry. Dox/Pac Lac-BSA NPs were fabricated utilizing high-pressure homogenization and evaporation with Nab (R) (nanoparticle albumin bound) technology. Dox/Pac Lac-BSA NPs were spherical and well-dispersed, with a 148.7 +/- 13.8 nm particle size and -54.1 +/- 0.7 mV zeta potential at a 100% Lac-BSA feed ratio. Combined Dox and Pac synergistic cytotoxicity was confirmed in Hep G2 cells. Specifically, the inhibitory concentration (IC50; 0.21 +/- 0.02 mu g/ml) for Dox/Pac Lac-BSA NPs was 3.2 time lower than plain Dox/Pac BSA NPs (IC50; 0.68 +/- 0.04 mu g/ml). Also, Dox/Pac Lac-BSA NPs exhibited better internalizing in Hep G2 cells (61.8% vs. 14.4% for Dox) and spheroids compared to Dox/Pac BSA NPs. Finally, Dox/Pac Lac-BSA NPs displayed much greater localization into ICR mice livers compared to Dox/Pac BSA NPs. This was indicated by the presence of NP lactose residues revealed by a galactose inhibition study. Based on these results, we suggest that lactose-modified albumin-based nanoparticles fabricated with the Nab (R) technique can be a potential therapeutic vector for treating HCC via hepatocyte targeting. (C) 2017 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by a grant (16173MFDS542) from Ministry of Food and Drug Safety in 2016. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Albumin nanoparticles | en_US |
dc.subject | Lactose | en_US |
dc.subject | Liver targetability | en_US |
dc.subject | Hepatocellular carcinoma | en_US |
dc.subject | Asialoglycoprotein receptor | en_US |
dc.subject | Nab (R) Technology | en_US |
dc.subject | DRUG-DELIVERY-SYSTEMS | en_US |
dc.subject | SERUM-ALBUMIN | en_US |
dc.subject | ASIALOGLYCOPROTEIN RECEPTOR | en_US |
dc.subject | TARGETED DELIVERY | en_US |
dc.subject | LUNG-CANCER | en_US |
dc.subject | IN-VIVO | en_US |
dc.subject | LIVER | en_US |
dc.subject | CARRIER | en_US |
dc.subject | IMPACT | en_US |
dc.subject | TRAIL | en_US |
dc.title | Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma | en_US |
dc.type | Article | en_US |
dc.relation.volume | 152 | - |
dc.identifier.doi | 10.1016/j.colsurfb.2017.01.017 | - |
dc.relation.page | 183-191 | - |
dc.relation.journal | COLLOIDS AND SURFACES B-BIOINTERFACES | - |
dc.contributor.googleauthor | Thao, Le Quang | - |
dc.contributor.googleauthor | Lee, Changkyu | - |
dc.contributor.googleauthor | Kim, Bomi | - |
dc.contributor.googleauthor | Lee, Sungin | - |
dc.contributor.googleauthor | Kim, Tae Hwan | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.contributor.googleauthor | Lee, Eun Seong | - |
dc.contributor.googleauthor | Oh, Kyung Taek | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Yoo, Sun Dong | - |
dc.contributor.googleauthor | Youn, Yu Seok | - |
dc.relation.code | 2017001472 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.